NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% ...

In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...

Aethlon's Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. Read the full article at Investorideas.com According to News-Medical.net, "Immunotherapy, which works ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

NuCana's American depositary receipts nearly doubled on Monday after the company reported positive data for its metastatic melanoma treatment. In premarket trading ADRs were up $2.44 to $4.98. However ...

Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 ...